The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 10 February 2021 at 7.00am under RNS No 5306O.
The announcement should have stated the percentage holding following the purchase of shares by Dr John Brown as 0.049% instead of 0.49% as previously reported.
All other details remain unchanged.
The full amended text is shown below.
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Director / PDMR Shareholding
Manchester, UK - 10 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it was notified on 9 February 2021 that Dr John Brown, a Director of the Company, purchased 102,450 Ordinary Shares of 0.10p each at a price of 12.2 pence per Ordinary Share via a pension fund held in his name on 9 February 2021.
Following this purchase, Dr John Brown holds 352,450 Ordinary Shares in the Company which represents 0.049% of the Company's issued share capital.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Dr John Brown
| |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| Yourgene Health plc | |||
| b)
| LEI
| 213800UUIT8BZE7QEH33 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares of 0.1p each | |||
| | | ||||
| Identification code | ISIN: GB00BN31ZD89 | ||||
| | | ||||
| b)
| Nature of the transaction
| Purchase | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | 12.2 pence per share | 102,450 | | |
| | | | | | |
| d)
| Aggregated information | N/A | |||
| | | ||||
| - Aggregated volume | | ||||
| | | ||||
| - Price | | ||||
| | | ||||
| e)
| Date of the transaction
| 9 February 2021 | |||
| f)
| Place of the transaction
| UK | |||
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.
| Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 | |||
| Barry Hextall, Chief Financial Officer | | |||
| Joanne Cross, Director of Marketing | | |||
| | | |||
| Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | |||
| Liam Murray / James Caithie / Ludovico Lazzaretti |
| |||
| N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | |||
| Aubrey Powell / Tom Salvesen / George Tzimas | | |||
| | | |||
| Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | |||
| Nicholas Moore / Matthew Blawat / Ben Maddison | | |||
| | | |||
| Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | |||
| Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | |||
| | | |
| |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
